Clinical Trial Update: A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study evaluating armored CD19-targeted CAR T cells in patients with relapsed or refractory chronic lymphocytic leukemia; status is active but not recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Armored CD19-targeted CAR T cells (CD19-targeted CAR T cell therapy)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Chronic Lymphocytic Leukemia (CLL), Relapsed | Phase 1 | Status: ACTIVE_NOT_RECRUITING